Co-occurrence of mixed proteinopathies in late-stage Huntington's disease
- PMID: 29134321
- DOI: 10.1007/s00401-017-1786-7
Co-occurrence of mixed proteinopathies in late-stage Huntington's disease
Abstract
Accumulating evidence highlights the potential role of mixed proteinopathies (i.e., abnormal protein aggregation) in the development of clinical manifestations of neurodegenerative diseases (NDD). Huntington's disease (HD) is an inherited NDD caused by autosomal-dominant expanded CAG trinucleotide repeat mutation in the gene coding for Huntingtin (Htt). Previous studies have suggested the coexistence of phosphorylated-Tau, α-synuclein (α-Syn) and TAR DNA-binding protein 43 (TDP-43) inclusions in HD. However, definite evidence that HD pathology in humans can be accompanied by other proteinopathies is still lacking. Using human post-mortem putamen samples from 31 controls and 56 HD individuals, we performed biochemical analyses of the expression, oligomerization and aggregation of Tau, α-Syn, TDP-43, and Amyloid precursor protein (APP)/Aβ. In HD brain, we observed reduced soluble protein (but not mRNA) levels of Htt, α-Syn, and Tau. Our results also support abnormal phosphorylation of Tau in more advanced stages of disease. Aberrant splicing of Tau exons 2, 3 (exclusion) and 10 (inclusion) was also detected in HD patients, leading to higher 0N4R and lower 1N3R isoforms. Finally, following formic acid extraction, we observed increased aggregation of TDP-43, α-Syn, and phosphorylated-Tau during HD progression. Notably, we observed that 88% of HD patients with Vonsattel grade 4 neuropathology displayed at least one non-Htt proteinopathy compared to 29% in controls. Interestingly, α-Syn aggregation correlated with Htt, TDP-43 and phosphorylated-Tau in HD but not in controls. The impact of this work is twofold: (1) it provides compelling evidences that Tau, α-Syn and TDP-43 proteinopathies are increased in HD, and (2) it suggests the involvement of common mechanisms leading to abnormal accumulation of aggregation-prone proteins in NDD. Further studies will be needed to decipher the impact of these proteinopathies on clinical manifestation of HD.
Keywords: Alpha-synuclein; Amyloid precursor protein; Human; Huntingtin; Huntington’s disease; Proteinopathy; Putamen; Splicing impairment; TAR DNA-binding protein 43; Tau.
Similar articles
-
Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington's Disease Brain.Neuroscience. 2023 May 10;518:54-63. doi: 10.1016/j.neuroscience.2022.07.014. Epub 2022 Jul 19. Neuroscience. 2023. PMID: 35868517
-
Aberrant splicing in Huntington's disease accompanies disrupted TDP-43 activity and altered m6A RNA modification.Nat Neurosci. 2025 Feb;28(2):280-292. doi: 10.1038/s41593-024-01850-w. Epub 2025 Jan 6. Nat Neurosci. 2025. PMID: 39762660 Free PMC article.
-
Pathogenic TDP-43 accelerates the generation of toxic exon1 HTT in Huntington's disease knock-in mice.Aging Cell. 2024 Dec;23(12):e14325. doi: 10.1111/acel.14325. Epub 2024 Aug 26. Aging Cell. 2024. PMID: 39185703 Free PMC article.
-
Faulty splicing and cytoskeleton abnormalities in Huntington's disease.Brain Pathol. 2016 Nov;26(6):772-778. doi: 10.1111/bpa.12430. Brain Pathol. 2016. PMID: 27529534 Free PMC article. Review.
-
Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.J Huntingtons Dis. 2023;12(1):1-13. doi: 10.3233/JHD-230569. J Huntingtons Dis. 2023. PMID: 37092231 Free PMC article. Review.
Cited by
-
Looking at the Pretty "Phase" of Membraneless Organelles: A View From Drosophila Glia.Front Cell Dev Biol. 2022 Feb 7;10:801953. doi: 10.3389/fcell.2022.801953. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35198559 Free PMC article. Review.
-
Age-Dependent Increase in Tau Phosphorylation at Serine 396 in Huntington's Disease Prefrontal Cortex.J Huntingtons Dis. 2023;12(3):267-281. doi: 10.3233/JHD-230588. J Huntingtons Dis. 2023. PMID: 37694372 Free PMC article.
-
Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model.Front Cell Dev Biol. 2022 Mar 21;10:863089. doi: 10.3389/fcell.2022.863089. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35386195 Free PMC article.
-
Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntington's Disease.Front Cell Neurosci. 2020 Jan 17;13:574. doi: 10.3389/fncel.2019.00574. eCollection 2019. Front Cell Neurosci. 2020. PMID: 32009905 Free PMC article. Review.
-
Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.Acta Pharmacol Sin. 2025 Jun;46(6):1511-1538. doi: 10.1038/s41401-024-01455-w. Epub 2025 Jan 31. Acta Pharmacol Sin. 2025. PMID: 39890942 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous